{"filing":{"accession_number":"0001193125-26-350425","cik":"0001498382","ticker":"HURA","company_name":"TuHURA Biosciences, Inc./NV","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"hura-20260814.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1498382/000119312526350425/hura-20260814.htm"},"events":[{"id":27736,"run_id":25311,"accession_number":"0001193125-26-350425","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"TuHURA Biosciences issued a press release on August 14, 2026, reporting financial results for the second quarter ended June 30, 2026, including R\u0026D expenses ($6.6M vs. $4.9M YoY), G\u0026A expenses ($2.1M vs. $1.9M YoY), cash position ($1.0M), and operating cash flows. The disclosure is a standard quarterly earnings release with financial metrics and a corporate update, filed under Item 2.02 and attached as Exhibit 99.1.","company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29396,"accession_number":"0001193125-26-350425","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"TuHURA Biosciences issued a press release on August 14, 2026, reporting financial results for the second quarter ended June 30, 2026, including R\u0026D expenses ($6.6M vs. $4.9M YoY), G\u0026A expenses ($2.1M vs. $1.9M YoY), cash position ($1.0M), and operating cash flows. The disclosure is a standard quarterly earnings release with financial metrics and a corporate update, filed under Item 2.02 and attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:52:37.897201+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29396,"accession_number":"0001193125-26-350425","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"TuHURA Biosciences issued a press release on August 14, 2026, reporting financial results for the second quarter ended June 30, 2026, including R\u0026D expenses ($6.6M vs. $4.9M YoY), G\u0026A expenses ($2.1M vs. $1.9M YoY), cash position ($1.0M), and operating cash flows. The disclosure is a standard quarterly earnings release with financial metrics and a corporate update, filed under Item 2.02 and attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:52:37.897201+00:00","company_name":"TuHURA Biosciences, Inc./NV","ticker":"HURA","filing_date":"2026-08-14"}]}